UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 or 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): June 9, 2004
La Jolla Pharmaceutical Company
| Delaware | 0-24274 | 33-0361285 | ||
| (State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
| 6455 Nancy Ridge Drive, San Diego, California | 92121 | |
| (Address of Principal Executive Offices) | (Zip Code) |
Registrant’s telephone number, including area code: (858) 452-6600
N/A
| Item 5. Other Events and Required FD Disclosure. | ||||||||
| Item 7. Financial Statements, Pro Forma Financial Information and Exhibits. | ||||||||
| SIGNATURES | ||||||||
| EXHIBIT INDEX | ||||||||
| EX-99.1 | ||||||||
| EX-99.2 | ||||||||
Item 5. Other Events and Required FD Disclosure.
On June 9, 2004, the Company issued a press release announcing that Steven B. Engle, the Company’s Chief Executive Officer, would present at the Third Annual Needham Biotechnology Conference on June 17, 2004. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
On June 10, 2004, the Company issued a press release announcing that the Company would present previously released results from its Phase 2/3 and Phase 3 clinical trials of Riquent® (abetimus sodium) at EULAR’s Annual European Congress of Rheumatology on June 9–12, 2004. A copy of the press release is attached hereto as Exhibit 99.2 and is incorporated herein by reference.
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.
(c) Exhibits. The following exhibits are filed with this report on Form 8-K:
| Exhibit | ||
| Number |
Description of Exhibit |
|
99.1
|
Needham Biotechnology Conference Press Release | |
99.2
|
EULAR Annual European Congress of Rheumatology Press Release |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| LA JOLLA PHARMACEUTICAL COMPANY |
||||
| Date: June 10, 2004 | By: | /s/ Gail A. Sloan | ||
| Gail A. Sloan | ||||
| Vice President of Finance and Controller | ||||